阿立哌唑与氯丙嗪治疗精神分裂症对照研究

A comparative study between aripiprazole and chlorpromazine in the treatment of schizophrenia.

目的探讨阿立哌唑与氯丙嗪对首发精神分裂症患者的临床疗效及安全性。方法72例精神分裂症患者随机分为两组,分别给予阿立哌唑与氯丙嗪,治疗8周,用阳性与阴性症状表(PANSS)和副反应量表(TESS)评定疗效和不良反应。结果阿立哌唑组疗效优于氯丙嗪组(P〈0.05),阿立哌唑不良反应显著少于氯丙嗪(P〉0.05)。结论阿立哌唑是一种安全有效的抗精神病药。

Objective To explore the clinical efficacy and side effects of aripiprazole and chlorpromazine in the treatment of first-episode schizophrenia. Methods A total of 72 schizophrenic inpatients were randomly divided into aripiprazole group or chlorpromazine group for 8 weeks. PANSS and TESS were used to evaluate the efficacy and side effects respectively. Results There was significant difference in effecacy between two groups. Aripiprazole had fewer side effects than chlorpromazine. Conclusion Aripiprazole is a safe and effective antipcychotic drug.